Zhou‐Yan Bian

2.6k total citations
63 papers, 2.2k citations indexed

About

Zhou‐Yan Bian is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Zhou‐Yan Bian has authored 63 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Cardiology and Cardiovascular Medicine, 33 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Zhou‐Yan Bian's work include Cardiac Fibrosis and Remodeling (32 papers), Signaling Pathways in Disease (16 papers) and Peptidase Inhibition and Analysis (7 papers). Zhou‐Yan Bian is often cited by papers focused on Cardiac Fibrosis and Remodeling (32 papers), Signaling Pathways in Disease (16 papers) and Peptidase Inhibition and Analysis (7 papers). Zhou‐Yan Bian collaborates with scholars based in China, United States and Canada. Zhou‐Yan Bian's co-authors include Qizhu Tang, Hongliang Li, Ling Yan, Heng Zhou, Wei Deng, Jia Dai, Yuan Yuan, Zhi‐Gang She, Jing Zong and Lihua Zhu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Zhou‐Yan Bian

63 papers receiving 2.2k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Zhou‐Yan Bian 1.1k 739 270 259 258 63 2.2k
Nobuyuki Marui 1.0k 0.9× 618 0.8× 449 1.7× 211 0.8× 236 0.9× 39 2.7k
Zheng Yang 814 0.7× 659 0.9× 134 0.5× 144 0.6× 163 0.6× 51 1.7k
Wu Luo 1.3k 1.2× 414 0.6× 463 1.7× 198 0.8× 244 0.9× 92 2.5k
Yuan Yuan 853 0.8× 522 0.7× 230 0.9× 118 0.5× 201 0.8× 81 2.0k
Qinghua Lu 988 0.9× 279 0.4× 206 0.8× 282 1.1× 263 1.0× 70 1.9k
Tomonaga Ichikawa 1.3k 1.1× 296 0.4× 375 1.4× 152 0.6× 284 1.1× 47 2.3k
Luisa Lenti 948 0.8× 363 0.5× 474 1.8× 136 0.5× 207 0.8× 44 2.5k
Daisaku Masuda 684 0.6× 645 0.9× 227 0.8× 188 0.7× 323 1.3× 96 2.5k
Ilaria Zanotti 883 0.8× 199 0.3× 279 1.0× 326 1.3× 372 1.4× 64 2.5k
Hai‐Han Liao 666 0.6× 434 0.6× 145 0.5× 127 0.5× 128 0.5× 42 1.4k

Countries citing papers authored by Zhou‐Yan Bian

Since Specialization
Citations

This map shows the geographic impact of Zhou‐Yan Bian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhou‐Yan Bian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhou‐Yan Bian more than expected).

Fields of papers citing papers by Zhou‐Yan Bian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhou‐Yan Bian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhou‐Yan Bian. The network helps show where Zhou‐Yan Bian may publish in the future.

Co-authorship network of co-authors of Zhou‐Yan Bian

This figure shows the co-authorship network connecting the top 25 collaborators of Zhou‐Yan Bian. A scholar is included among the top collaborators of Zhou‐Yan Bian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhou‐Yan Bian. Zhou‐Yan Bian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yan, Jie, Xiaoyang Zhou, Zhou‐Yan Bian, & Si‐Chi Xu. (2019). Antithrombotic therapy and outcome in patients with ischemic cardiomyopathy complicated by left ventricular thrombus. 3(2). 69–73. 1 indexed citations
2.
Jiang, Xiaohan, Qingqing Wu, Xiao Yang, et al.. (2016). GW27-e0332 Evodiamine inhibits cardiac fibrosis and endothelial to mesenchymal transition. Journal of the American College of Cardiology. 68(16). C13–C13. 1 indexed citations
3.
4.
Liu, Yuan, Hai‐Han Liao, Wei Liu, et al.. (2015). Toll-like receptor 5 deficiency attenuates interstitial cardiac fibrosis and dysfunction induced by pressure overload by inhibiting inflammation and the endothelial–mesenchymal transition. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1852(11). 2456–2466. 44 indexed citations
5.
Zhang, Ning, Zheng Yang, Yuan Yuan, et al.. (2015). Naringenin attenuates pressure overload-induced cardiac hypertrophy. Experimental and Therapeutic Medicine. 10(6). 2206–2212. 44 indexed citations
6.
Yuan, Yuan, Heng Zhou, Qingqing Wu, et al.. (2015). Puerarin attenuates the inflammatory response and apoptosis in LPS-stimulated cardiomyocytes. Experimental and Therapeutic Medicine. 11(2). 415–420. 34 indexed citations
7.
Zhou, Heng, Haipeng Guo, Jing Zong, et al.. (2014). ATF3 regulates multiple targets and may play a dual role in cardiac hypertrophy and injury. International Journal of Cardiology. 174(3). 838–839. 26 indexed citations
8.
Yuan, Yuan, Jing Zong, Heng Zhou, et al.. (2013). Puerarin attenuates pressure overload-induced cardiac hypertrophy. Journal of Cardiology. 63(1). 73–81. 68 indexed citations
9.
Deng, Wei, Yi Fang, Heng Zhou, et al.. (2013). Hesperetin protects against cardiac remodelling induced by pressure overload in mice. Journal of Molecular Histology. 44(5). 575–585. 41 indexed citations
10.
Zong, Jing, Mohamed Salim, Heng Zhou, et al.. (2013). NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload. Laboratory Investigation. 93(10). 1128–1136. 34 indexed citations
11.
Zhou, Heng, Yuan Yuan, Wei Deng, et al.. (2013). Paeoniflorin attenuates pressure overload-induced cardiac remodeling via inhibition of TGFβ/Smads and NF-κB pathways. Journal of Molecular Histology. 44(3). 357–367. 44 indexed citations
12.
Zong, Jing, Wei Deng, Heng Zhou, et al.. (2013). 3,3′-Diindolylmethane Protects against Cardiac Hypertrophy via 5′-Adenosine Monophosphate-Activated Protein Kinase-α2. PLoS ONE. 8(1). e53427–e53427. 21 indexed citations
13.
Zong, Jing, Qingqing Wu, Heng Zhou, et al.. (2012). 3,3′-Diindolylmethane attenuates cardiac H9c2 cell hypertrophy through 5′-adenosine monophosphate-activated protein kinase-α. Molecular Medicine Reports. 12(1). 1247–1252. 14 indexed citations
14.
Zhang, Yan, et al.. (2011). HSP75 protects against cardiac hypertrophy and fibrosis. Journal of Cellular Biochemistry. 112(7). 1787–1794. 22 indexed citations
15.
Guo, Haipeng, Heng Zhou, Jing Zong, et al.. (2011). Gastrodin protects against cardiac hypertrophy and fibrosis. Molecular and Cellular Biochemistry. 359(1-2). 9–16. 61 indexed citations
16.
Ai, Wen, Yan Zhang, Qi‐Zhu Tang, et al.. (2010). Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR‐dependent signaling. Journal of Cellular Biochemistry. 110(5). 1111–1122. 43 indexed citations
17.
Wang, Lang, Lihua Zhu, Hong Jiang, et al.. (2010). Grape seed proanthocyanidins attenuate vascular smooth muscle cell proliferation via blocking phosphatidylinositol 3‐kinase‐dependent signaling pathways. Journal of Cellular Physiology. 223(3). 713–726. 33 indexed citations
18.
Liu, Chen, Feng Cao, Qizhu Tang, et al.. (2010). Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. The Journal of Nutritional Biochemistry. 21(12). 1238–1250. 92 indexed citations
19.
Bian, Zhou‐Yan, Jun Cai, Zhi‐Gang She, et al.. (2008). Cellular repressor of E1A‐stimulated genes attenuates cardiac hypertrophy and fibrosis. Journal of Cellular and Molecular Medicine. 13(7). 1302–1313. 48 indexed citations
20.
Cai, Jun, Fangfang Yi, Zhou‐Yan Bian, et al.. (2008). Crocetin protects against cardiac hypertrophy by blocking MEK‐ERK1/2 signalling pathway. Journal of Cellular and Molecular Medicine. 13(5). 909–925. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nobuyuki Marui Breakdown of academic impact, for papers by Zheng Yang Breakdown of academic impact, for papers by Wu Luo Breakdown of academic impact, for papers by Yuan Yuan Breakdown of academic impact, for papers by Qinghua Lu Breakdown of academic impact, for papers by Tomonaga Ichikawa Breakdown of academic impact, for papers by Luisa Lenti Breakdown of academic impact, for papers by Daisaku Masuda Breakdown of academic impact, for papers by Ilaria Zanotti Breakdown of academic impact, for papers by Hai‐Han Liao
Rankless by CCL
2026